In August, NICE published guidance on some new topics: atrial fibrillation – dronedarone; Barrett’s oesophagus – ablative therapy; chronic heart failure; gastrointestinal stromal tumours – imatinib (adjuvant); hypertension in pregnancy; psoriatic arthritis – etanercept, infliximab and adalimumab; rheumatoid arthritis – drugs for treatment after failure of a TNF inhibitor; rheumatoid arthritis – tocilizumab; and transient loss of consciousness in adults and young people. An NPCi blog has explored some of the new guidance.
On 10 September, NICE also recommended liraglutide 1.2 mg daily for some people who have type 2 diabetes, in draft guidance. It sets out the circumstances in which liraglutide can be used in dual and triple therapy regimens and says that liraglutide 1.8 mg is not recommended. Final guidance is expected in October, says NICE.